NCT06779929View on ClinicalTrials.gov

Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)

Active, not recruitingOBSERVATIONAL

Enrollment

50,000

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

June 15, 2025

Conditions

Type 2 Diabetes

Interventions

DRUG

Tirzepatide

Tirzepatide

DRUG

Dulaglutide

Dulaglutide

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER